MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.
Liu Y, Deshmukh S, Ma Y, Carter J, Wu S, Xiu J, Norton N, Ruddy K, Ruddy K, Perez E, Gandhi S, Barreto Coelho P, Lustberg M, Goetz M, Joensuu H, Sledge G, Thompson E, Chumsri S. MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial. Journal Of Clinical Oncology 2025, 43: 570-570. DOI: 10.1200/jco.2025.43.16_suppl.570.Peer-Reviewed Original ResearchTriple-negative BCMHC-I expressionCD8+ T cellsHER2+Overall survivalI expressionBC subtypesBreast cancerMHC-IT cellsHLA-CAssociated with higher immune infiltrationDownregulation of MHC-I expressionFrequency of PD-L1 positivityHLA-AHLA-BT cell inflamed scoreExpression of HLA-AInfiltration of B cellsMHC class I expressionSubtypes of breast cancerMechanisms of immune evasionReal-world overall survivalHormone receptor-positivePD-L1 positivity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply